OncLive - Bringing the Oncology Community Together

Home

Targeted Therapies

Hennessy's Highlights

Conference Coverage

2012 ASCO Annual Meeting Precoverage

Precoverage of the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, starts May 16, 2012.

Conference Coverage

Oncology Nursing Society Congress

Oncology Nursing Society (ONS) 37th Annual Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.

Revised View Enhances Provenge Overall Survival Data

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Interactive Publication

Impact of Dose Intensity
on Patient Outcomes

New insight into issues surrounding relative dose intensity, which includes the impact of febrile neutropenia and chemotherapy dose intensity on patient outcomes.

OncLive TV - A Network of Your Peers

Dr. Spector Discusses Breast Cancer Heterogeneity

Dr. Spector Discusses Breast Cancer Heterogeneity

Dr. Ansell on Waldenström Macroglobulinemia Treatments

Dr. Ansell on Waldenström Macroglobulinemia Treatments

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

Dr. Dreicer on Utilizing New Prostate Cancer Therapies

Dr. Dreicer on Utilizing New Prostate Cancer Therapies

>>> Click here for more videos

Latest Oncology Headlines

2012 ASCO Pre-Meeting Video Coverage

2012 ASCO Pre-Meeting Video Coverage

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

Conferences > 2012 ASCO Annual Meeting

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Conferences > 2012 ASCO Annual Meeting

Premature Aromatase Inhibitor Discontinuation Is Common

Premature Aromatase Inhibitor Discontinuation Is Common

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Oncology & Biotech News > Clinical Trial Reports

Bending the Cost Curve and Here Come the Judge(s)

Bending the Cost Curve and Here Come the Judge(s)

Lately, business and government have done more to "move the needle" in changing healthcare delivery than physicians, scientists, and other clinical professionals.

Oncology & Biotech News > From the Editor

>>> Click here for more articles

Oncology Resources

Editor's Corner

Andrew Pecora, MD
Oncology & Biotech News
Bending the Cost Curve and Here Come the Judge(s)

Maurie Markman, MD
OncologyLive
Going Beyond the Label: Targeted Therapies Present New Questions in Clinical Use

Andre Goy, MD, MS
Contemporary Oncology
Personalized Medicine: A Promising Future in Oncology Practice

Lisa Schulmeister, RN, OCN
OncLive Nursing
Nurses Needed for the Nurses' Health Study

>>>View the entire advisory board

Most Popular Right Now

New Therapies for Prostate Cancer: The Practicalities

Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?

5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance

PCPs Highly Unaware of Long-Term Chemotherapy Side Effects

Sipuleucel-T Stimulates Response in Localized Setting, Study Finds

Oncology Publications

Previous Tab

Next Tab

External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest

OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives

About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions

Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.